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Abstract
Resistant starch (RS) has been shown to beneficially affect insulin sensitivity in healthy
individuals and those with metabolic syndrome, but its effects on human type 2 diabetes
(T2DM) are unknown. This study aimed to determine the effects of increased RS consumption
on insulin sensitivity and glucose control and changes in postprandial metabolites and body
fat in T2DM. Seventeen individuals with well-controlled T2DM (HbA1c 46.6G2 mmol/mol)
consumed, in a random order, either 40 g of type 2 RS (HAM-RS2) or a placebo, daily for
12weekswith a 12-weekwashout period in between. At the end of each intervention period,
participants attended for three metabolic investigations: a two-step euglycemic–hyper-
insulinemic clamp combinedwith an infusion of [6,6-2H2] glucose, ameal tolerance test (MTT)
with arterio-venous sampling across the forearm, and whole-body imaging. HAM-RS2
resulted in significantly lower postprandial glucose concentrations (PZ0.045) and a trend for
greater glucose uptake across the forearmmuscle (PZ0.077); however, there was no effect of
HAM-RS2 onhepatic or peripheral insulin sensitivity, or onHbA1c. Fasting non-esterified fatty
acid (NEFA) concentrations were significantly lower (PZ0.004) and NEFA suppression was
greater during the clamp with HAM-RS2 (PZ0.001). Fasting triglyceride (TG) concentrations
and soleus intramuscular TG concentrations were significantly higher following the
consumption of HAM-RS2 (PZ0.039 and PZ0.027 respectively). Although fasting GLP1
concentrations were significantly lower following HAM-RS2 consumption (PZ0.049),
postprandial GLP1 excursions during theMTTwere significantly greater (PZ0.009). HAM-RS2
did not improve tissue insulin sensitivity in well-controlled T2DM, but demonstrated
beneficial effects on meal handling, possibly due to higher postprandial GLP1.
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Introduction
It is estimated that 25.8 million children and
adults in the USA have diabetes (8.3% of the
population), equating to a health cost of $218 billion
(w10% of total healthcare expenditure). Lifestyle
interventions, predominantly modulations to dietary
intake, are the first-line strategy in diabetes treat-
ment and remain a constant theme throughout
management.
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Traditionally, dietary fibers have been used to manage
blood glucose concentration and have been linked to
improved glycemic control in both healthy groups
and those with diabetes through various meta-analyses (1).
The USDA-recommended fiber intake is 14 g/1000 kcal in
healthy individuals, with evidence currently lacking to
recommend a higher intake in people with diabetes. This
was highlighted in a scientific advisory committee (SACN)
statement on nutrition that stated, although cereal fiber
intake has been associated with a reduced incidence of type
2 diabetes (T2DM) and metabolic risk factors such as
insulin resistance, the majority of evidence relates to
T2DM prevention. While this is important given the
current obesity epidemic, it cannot necessarily be translated
into health benefits for those patients with T2DM (2).
Resistant starch (RS) is a type of cereal fiber and has
been shown to have beneficial effects on insulin sensitivity
and fatty acid (FA) metabolism in both healthy individuals
and those with metabolic syndrome (3, 4, 5, 6, 7).
However, the efficacy of RS in individuals with T2DM
has not been investigated.
Animal studies have consistently shown that RS
improves glucose and insulin metabolism through
increased postprandial GLP1 secretion due to stimulation
of the colonic enteroendocrine cells (8, 9). This can result
in improved insulin secretion. Most recently our own data
has shown restored first-phase insulin secretion in
metabolic syndrome (10); however, the lack of transla-
tional work has recently been highlighted (11). The ADA
position on RS states ‘there are no published long-term
studies in subjects with diabetes to prove benefits from
the use of resistant starch’ (12), whereas the Diabetes
Nutrition Study Group of the EASD (13) makes no
mention of RS, stating that ‘total dietary fiber should
ideally be more than 20 g/1000 kcal’. The current USA and
UK fiber intakes equate to w7 g and 6 g/1000 kcal,
respectively, falling short of even modest guideline daily
amounts (GDA).
The primary aim of the study was to translate the
beneficial effects of RS feeding reported in healthy and
insulin resistant groups, into similar observations in a
T2DM cohort. Using an integrated, whole-body approach,
stable isotope tracers to differentiate between changes
in hepatic and peripheral insulin sensitivity of glucose
uptake, body composition analysis using magnetic
resonance imaging (MRI) and magnetic resonance spec-
troscopy (MRS) to investigate changes in body fat depot
distribution, and a meal tolerance test (MTT) combined
with arterio-venous (A-V) sampling across muscle tissue,
for the first time we investigated the efficacy of increasing
RS intake to achieve total fiber intakes above the GDA in
individuals with T2DM.
Subjects and methods
Patients
Seventeen individuals with T2DM (12 males, five females;
mean age 55 (S.E.M. 2.4) years, mean BMI 30.6 (S.E.M. 1.3)
kg/m2) were enrolled in this study. All participants
had well-controlled diabetes (mean HbA1c levels of 46.6
(S.E.M. 2) mmol/mol at screening) and were diet and
exercise controlled (2/17), taking metformin (13/17) or
metformin and pioglitazone (2/17), were weight stable,
and excluded if they had a history of gastrointestinal,
cardiovascular, or other endocrine diseases.
The study was conducted according to the guidelines
laid down in the Declaration of Helsinki, and all
procedures were approved by the Kent NHS Research
Ethics Committee (10/H1101/29) and the University of
Surrey Research Ethics Committee. Written informed
consent was obtained from all patients. This trial was
registered via the International Standard Randomised
Controlled Trial Number 10727538.
Study design
The study was carried out as a single-blind, randomized
dietary intervention crossover study, comparing RS derived
from maize with a placebo that was matched for available
carbohydrate content. Participants were supplied with
supplements labeled either ‘A’ or ‘B’ and were not made
awareof their composition.Eachsupplementwasconsumed
daily for 12 weeks with a 12-week washout period between
interventions. During the last week of each intervention
period, participants completed a 7-day food and drink diary
and a 7-day bowel habit and symptom diary. Participants
attended for three study visits at the end of each interven-
tion: i) a two-step euglycemic–hyperinsulinemic clamp
combined with an infusion of [6,6-2H2] glucose, ii) a MTT
with A-V sampling across the forearmmuscle, and iii) a MRI
scan.Thefirst twostudieswereconductedat theRoyal Surrey
County Hospital, UK and the third at the MRC Clinical
Sciences Center, Hammersmith Hospital, UK. Before each
study visit, patients consumed a standard eveningmeal and
then fasted for 12 h.Theywere instructed toavoid strenuous
exercise and alcohol for the preceding 24 h.
Participants were randomized to either 67 g Hi-maize
260 (comprising 60% RS and 40% rapidly digestible starch
(RDS) providing 40 g type 2 RS derived from maize,
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as measured by The Association of Official Analytical
Chemists for total dietary fiber method 991.43) or 27 g
Amioca (100% RDS). Both supplements were supplied by
Ingredion, Inc. (Bridgewater, NJ, USA) in ready-to-use
sachets that were mixed into a beverage, and participants
were required to consume two sachets daily to obtain the
correct dosage. In the results and discussion, the Hi-maize
supplement will be referred to as HAM-RS2 and the
Amioca supplement as placebo.
Euglycemic–hyperinsulinemic clamp with stable
isotopes " Participants arrived fasting and following
voiding, body weight and composition were measured by
bioimpedance (Tanita, Arlington Heights, IL, USA). An i.v.
cannula was inserted into each arm for blood sampling
and for the glucose, insulin, and isotope infusions. An
initial blood samplewas collected andaprimed continuous
infusion of [6,6-2H2] glucose (170 mg; 1.7 mg/min) com-
menced. Once a steady state had been reached, five blood
samples were taken between 100 and 120 min. At 120 min,
the two-step euglycemic–hyperinsulinemic clamp was
started. Step one assessed hepatic (endogenous) glucose
production (EGP) and involved an insulin infusion
(Actrapid, Novo Nordisk, Bagsvaerd, Denmark) of
0.3 mU/kg per min (low dose) for 120 min. Step two
assessed insulin sensitivity of glucose uptake (disposal,
Rd) and involved an insulin infusion of 1.5 mU/kg permin
(high dose) for a further 180 min. Plasma glucose concen-
trations were maintained at fasting levels through a
variable infusion of 20% dextrose spiked with [6,6-2H2]
glucose (8 mg/g for low dose and 10 mg/g for the high
dose). Blood samples were taken every 10 min and blood
glucose concentrations measured immediately by the
glucose oxidase method using the YSI 2300 STAT Plus
(YSI Life Sciences, Fleet, UK). Additional samples were
taken during the steady state of the low (210–240 min) and
high (390–420 min) dose steps.
Owing to difficulties with venous access in some
individuals, the data for the euglycemic–hyperinsulinemic
clamp are presented for nZ15 only.
MTT with A-V sampling " Following a rest of 10 min,
carotid–femoral pulse wave velocity, brachial pulse wave
analysis (includingmeasures ofmean arterial pressure, aortic
pulse pressure, augmentation index, stroke volume, systolic
and diastolic aortic blood pressures, and total peripheral
resistance), and blood pressure were assessed using the
Vicorder system (Smart Medical, Inc., La Mirada, CA, USA).
To assess the metabolism of skeletal muscle in vivo, the
A-V difference across the forearm muscle was assessed as
described previously (5). Arterialized blood was obtained
from a cannula inserted into the hand that was placed in a
heated box (50 8C). Venous blood was obtained from a
cannula placed into deep muscle draining vein of the
opposite arm and the hand was occluded for 2 min before
drawing each sample using a wrist cuff inflated to
20 mmHg above systolic blood pressure. Oxygen satur-
ation was assessed at each site to ensure correct placement
and arterialization, with cutoffs of !60% O2 for venous
blood and O95% O2 for arterialized blood.
Two fasting blood samples were taken simultaneously
from both sites. Patients then consumed a standardized
liquid meal that did not contain either of the supplements
(436 kcal, 61.2 g carbohydrate, 11.9 g fat, and 0 g dietary
fiber) at time 0. Further blood samples were collected
simultaneously from both sites every half hour for 5 h.
Owing to difficulties with venous access, the post-
prandial data presented are for 16 patients only and the
A-V difference data are for 12 patients only.
Magnetic resonance imaging " Upon arrival at the
MRI unit, patients underwent whole-body MRI scanning
to measure total and regional adipose tissue (AT) contents,
as well as liver, pancreatic, and muscle proton MRS
(1H-MRS) measurements as described previously (3). As
not all individuals were suitable candidates for MRI
scanning, the data presented are for 14 patients only.
Biochemistry
Metabolites from the placebo and HAM-RS2 arms of the
trial were analyzed together with an intra-assay variation
!2.5% for all metabolites.
Plasma samples collected during the clamp were
analyzed enzymatically for glucose concentration using a
Cobas Mira (Roche Laboratories). Isotopic enrichment of
the same plasma samples was measured by gas chromato-
graphy–mass spectrometry on an HP5971A mass selective
detector (Agilent, Santa Clara, CA, USA). The enrichment
was determined using a penta-O-trimethylsilyl-D-glucose-
O-methoxime derivative analyzed by selected ion
monitoring of the ions at a charge-to-mass ratio of 319
and 321 (14). Plasma glucose concentrations from the
MTT were measured using the glucose oxidase method
on the YSI 2300 STAT Plus (YSI Life Sciences) with an
inter-assay coefficient of variation (CV) of 1.7%.
Plasma insulin concentrations during the clamp
and MTT were measured by ELISA (Millipore, Billerica,
MA, USA) with inter-assay CV !14% and intra-assay
CV !10%.
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Plasma triglyceride (TG), non-esterified FA (NEFA),
total cholesterol, and HDL-cholesterol concentrations
were measured using commercially available kits for the
ILab650 (Instrumentation Laboratory, Warrington, UK),
with all inter-assay CV values being !2.5% and all intra-
assay CV values being !1.5%.
Fasting tumor necrosis factor a (TNFa) and interleukin
6 (IL6) were measured by commercially available ELISA
Kits (2B Scientific, Upper Heyford, UK) with inter-assay CV
values !4 and !18% respectively and intra-assay CV
values !7 and !10% respectively. Plasma adiponectin
and leptin were measured using ELISA (Millipore) with
intra-assay CV of 3.6 and 4.4% respectively.
Blood samples for C-peptide and total GLP1 analyses
from the MTT were collected into potassium EDTA tubes
containing 200 kallikrein inhibiting units (KIU) aproti-
nin/ml of blood. Plasma samples were then measured
by ELISA (Millipore), with inter- and intra-assay CV values
!25 and!6.5% for C-peptide and GLP1 respectively.
Serum short-chain FAs (SCFAs) were measured using a
gas chromatography-basedmethod as described previously
(15, 16). For each sample, 1 ml was injected into a Hewlett
Packard 5890 Series II GC system fitted with a Nukol
Capillary Column (30 m!0.53 mm!1.0 mm, SUPELCO
Analytical, Poole, Dorset, UK) and flame ionization
detector. The peaks were integrated using Agilent Chem-
Station Software, and SCFA contents quantified by single-
point internal standardmethod. Peak identity and internal
response factors were determined using a 1 mMcalibration
cocktail, including acetic, propionic, iso-butyric, butyric,
iso-valeric, valeric, ethyl-butyric, and caproic acids.
A priori and retrospective sample size
Sample sizewas basedonnZ15 (7). Based on15participants
completing this crossover study (aZ0.05), there would be
an 82% probability of detecting a treatment difference of
73.7 mmol/l per min in glucose area under the curve (AUC)
0–120 min, based on the assumption of a treatment S.D. of
84, with postprandial glucose tolerance as the primary
outcomemeasure. Both A-V uptake andMRI scanningwere
not performed due to problems with vascular access and
unforeseenclaustrophobia inanumberofpatients.Basedon
the actual participant numbers, the retrospective power
estimate for detecting a difference in the A-V glucose uptake
into muscle was 84%, based on a treatment S.D. of 58 and a
measured treatment effect of 111 mmol/l per 100 ml tissue.
For theMRImeasures, the inter-individual variability found
in this T2DM cohort was much higher than expected based
on data available from those without diabetes. As such,
this secondary outcome was significantly underpowered
during the study, with only 21% power (aZ0.05) due to a
very high treatment variable S.D. of 4.2.
Calculations and statistical analyses
LDL-cholesterol was calculated using the Friedewald
equation (17). Fasted insulin sensitivity (%S) and b-cell
function (%B) were assessed by the homeostatic model
assessment (HOMA) (18), and postprandial insulin sensi-
tivity was calculated using the Matsuda index (19).
During the clamp, EGP and glucose Rd were calculated
using the model proposed by Steele (20) modified to
include the use of stable isotopes. The volume of
distribution was assumed to be 22% of body weight. The
calculation was also modified for the inclusion of [6,6-2H2]
glucose in the dextrose infusion (21). Before calculation
of glucose turnover, plasma glucose concentrations and
glucose enrichment time courses were smoothed using
optimal segments technique analysis (22). For each time
point, EGP and Rd were calculated. Data are expressed as
mean EGP and Rd from five sample values collected during
each steady state (basal, low, and high dose).
AUC was calculated using the trapezoid rule for
0–120 min (AUC0–120 min) for each of the postprandial
metabolites. Incremental AUC (iAUC) was also calculated
to allow for any significant differences in baseline
concentrations. During the MTT, A-V differences in
metabolite concentrationswere calculated.Total FAuptake
into muscle was calculated from the rate of TG and NEFA
removal across the tissue as described previously (5).
All dietary analyses were carried out using nutritional
analysis software (Dietplan6 Professional version, Forest-
field Software, Horsham, UK) and average daily intake was
calculated.
All statistical analyses were carried out using SPSS 19.0
for Windows. Statistical significance was taken as P!0.05.
All data were normalized and analyzed using paired
samples t-tests and time course data analyzed using
repeated-measures ANOVA. Owing to the heterogeneity
of the patient group, exploratory Pearson’s correlation
coefficients were computed to assess potential relation-
ships. For these correlations, percentage change after
consumption of HAM-RS2 compared with placebo was
calculated. All results are expressed as meanGS.E.M.
Results
The inclusion of both supplements into habitual diets was
well tolerated by the participants as assessed by the bowel
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habit and symptom diaries. The only reported side effect
was a mild but significant increase in the ratings of
flatulence with HAM-RS2 compared with placebo (1.1G
0.2 vs 0.7G0.1, respectively, PZ0.006, measured on a scale
of 0–4 (none to debilitating)).
There was no significant difference in energy intake
between the HAM-RS2 and placebo (2044G116 vs 2089G
119 kcal respectively). There was also no significant
difference in carbohydrate and fat intakes; however,
protein intakes were significantly lower with the HAM-
RS2 compared with the placebo (84.2G2.6 vs 92.3G4.8 g,
PZ0.043). As would be expected, mean fiber intake
increased significantly during the HAM-RS2 intervention
(60.1G1.3 compared with 22.7G1.9 g; P!0.001), which
can be directly attributed to the HAM-RS2 supplement.
Glucose metabolism and insulin sensitivity
There was no significant difference, between the HAM-RS2
and the placebo at the end of the 12-week intervention,
in fasting glucose or insulin (Table 1) and therefore no
significant difference in fasting insulin sensitivity or b-cell
function as assessed by HOMA (Table 1). Similarly, there
was no significant difference between the interventions in
long-term glucose control as assessed by HbA1c (Table 1).
During the two-step euglycemic–hyperinsulinemic
clamp, no difference was observed between interventions
in EGP at basal (placebo, 11.5G0.6 mmol/kg per min and
HAM-RS2, 10.7G0.7 mmol/kg per min) or during the low
dose insulin infusion (placebo, 4.6G0.3 mmol/kg per min
and HAM-RS2, 5.0G0.4 mmol/kg per min). No significant
differences were observed between interventions for
glucose Rd at basal (placebo, 11.9G0.5 mmol/kg per min
and HAM-RS2, 10.7G0.8 mmol/kg per min) or during the
high dose insulin infusions (placebo, 47.0G5.4 mmol/kg
per min and HAM-RS2, 47.3G6.0 mmol/kg per min). There
were no differences in insulin concentrations throughout
the clamp study. Postprandial glucose concentrations
during the MTT exhibited a significant treatment by
time interaction (PZ0.045; Fig. 1A); this translated as a
significant reduction in glucose AUC0–120 min with the
HAM-RS2 (PZ0.036). The A-V sampling across the forearm
muscle also showed a trend for higher glucose uptake with
HAM-RS2 compared with the placebo (PZ0.077; Fig. 1B).
The lower postprandial glucose concentrations with
HAM-RS2 were not associated with a significant lowering
of the plasma insulin concentration; however, there was
a significant time!treatment interaction effect on plasma
C-peptide concentrations (PZ0.038; data not shown).
There were no significant differences between the
interventions for postprandial insulin sensitivity assessed
by the Matsuda index (19).
Fat metabolism
Increased consumption of HAM-RS2 resulted in signifi-
cantly higher fasting TG concentrations (PZ0.039;
Table 1) compared with the placebo, with no effect on
cholesterol concentrations. After 12 weeks of increased
HAM-RS2 consumption, fasting NEFA concentrations
were significantly lower (PZ0.004; Table 1) and there
was greater differential suppression of NEFA by insulin
during the two-step clamp (PZ0.001; Fig. 2). During the
MTT, there was no effect of treatment on postprandial
Table 1 Anthropometric measurements, body fat depots, and
fasting plasma concentrations taken after 12 weeks supplemen-
tation with 40 g/day HAM-RS2 compared with placebo. MeanG
S.E.M. for 17 patients.
HAM-RS2 Placebo P value
Body weight (kg) 92.5G5.0 91.7G5.1 NS
BMI (kg/m2) 31.0G1.3 30.7G1.4 NS
Fat mass (kg)a 32.2G2.7 31.8G2.9 NS
Total AT (l)b 35.8G3.6 34.5G4.0 NS
Subcutaneous AT (l)b 26.2G2.9 25.6G3.3 NS
Internal AT (l)b 9.6G1.1 9.0G1.0 NS
IHCLb 9.7G2.7 10.0G3.3 NS
Pancreas fatb 13.7G3.9 10.5G3.2 NS
S-IMCLb 24.7G4.6 19.3G3.7 0.027
T-IMCLb 7.9G1.1 6.5G0.8 NS
HbA1c (mmol/mol) 46.8G1.5 47.9G2.0 NS
Glucose (mmol/l) 6.2G0.2 6.4G0.2 NS
Insulin (pmol/l) 49.1G7.4 51.0G9.5 NS
C-peptide (nmol/l) 0.7G0.1 0.7G0.1 NS
HOMA %S 116.3G15.1 115.9G13.9 NS
HOMA %B 67.5G7.1 63.5G6.8 NS
NEFA (mmol/l) 500G100 600G50 0.004
TG (mmol/l) 1.4G0.1 1.2G0.1 0.039
Total cholesterol
(mmol/l)
3.6G0.1 3.4G0.2 NS
HDL-cholesterol
(mmol/l)
1.0G0.1 1.0G0.1 NS
LDL-cholesterol
(mmol/l)
1.9G0.1 1.8G0.1 NS
GLP1 (pmol/l) 11.4G1.9 17.0G3.2 0.049
Leptin (ng/ml) 10.9G1.9 10.2G1.8 NS
Adiponectin (ng/ml) 8232G1249 7701G879 NS
TNFa (pg/ml) 5.1G2.6 13.2G3.9 0.013
IL6 (pg/ml) 6.5G1.8 3.8G1.5 NS
Acetate (mmol/l) 99.1G1.2 98.3G6.1 NS
Propionate (mmol/l) 4.0G0.2 7.5G1.4 0.021
Butyrate (mmol/l) 0.6G0.1 1.1G0.1 !0.001
AT, adipose tissue; IHCL, intrahepatocellular lipid; S-IMCL, soleus intramyo-
cellular lipid; T-IMCL, tibialis IMCL; HOMA%S, fasted oral insulin sensitivity
assessed by homeostasis model assessment; HOMA %B, b-cell function,
assessed by HOMA (18).
aMeasured by bioimpedance (nZ16).
bBody fat depots determined by MRS scanning (nZ14).
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concentrations of NEFA or TG and no effect on FA flux as
measured by A-V sampling (data not shown); however, the
percentage increase in FA uptake intomuscle from placebo
to HAM-RS2 intake correlated significantly both with an
increase in glucose disposal (Rd) measured during the
clamp study (PZ0.036) and with glucose flux measured by
A-V sampling in the postprandial state (PZ0.004).
Inflammatory markers, SCFA, and hormones
Increased intake of HAM-RS2 for 12 weeks resulted in
significantly lower fasting TNFa concentrations (PZ0.013;
Table 1) but had no effects on fasting IL6 concentrations
(Table 1). Therewas also no effect ofHAM-RS2 treatment on
either fasting plasma leptin or adiponectin concentrations
(Table 1). Fasting plasma propionate and butyrate concen-
trations were significantly lower (PZ0.021 and P!0.001
respectively) following the HAM-RS2 compared with the
placebo, but there were no significant differences between
treatments for plasma acetate concentrations (Table 1).
Fasting GLP1 concentrations were significantly lower
(PZ0.049) following HAM-RS2 compared with placebo;
however, there was a significantly greater meal GLP1
excursion with HAM-RS2 than with the placebo (PZ0.009;
Fig. 1C).
Vascular function and blood pressure
There were no significant differences in blood pressure,
carotid–femoral pulse wave velocity or any of the clinical
markers of vascular function (data not shown) following
HAM-RS2.
Body weight and composition
Despite no significant differences in body weight, BMI, or
fat mass (Table 1), following 12 weeks of increased HAM-
RS2 intake, soleus intramyocellular lipid (S-IMCL) content
was significantly higher comparedwith placebo (PZ0.027;
Table 1); the tibialis IMCL (T-IMCL) was also higher
following HAM-RS2 although not significantly (Table 1).
This increase in S-IMCL was significantly correlated with
the reduction in both fasting NEFA (PZ0.022) and HbA1c
(PZ0.017). There were no other significant differences
between interventions for liver, pancreatic or AT fat
depots, assessed by MRS scanning.
Discussion
Although consumption of HAM-RS2 has been extensively
investigated in healthy groups and those with the
metabolic syndrome (3, 4, 5, 6, 7, 10), this work represents
the first attempt at translation of these findings into an
efficacious dietary treatment for human T2DM. In
individuals with well-controlled diabetes (mean HbA1c,
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Figure 1
Postprandial glucose concentrations (A), glucose flux into the muscle tissue
measured with arterio-venous sampling across the forearm muscle (B), and
change from baseline postprandial GLP1 concentrations (C) during the
MTT at the end of 12 weeks supplementation with HAM-RS2 (filled circle)
compared with placebo (open circle). MeanCS.E.M.s for 16 patients
(A and C) and 12 patients (B). There was a significant treatment!time
interaction for the postprandial glucose concentrations as assessed
by repeated measures ANOVA (PZ0.045), which corresponded to a
significantly reduced AUC0–120 min following the HAM-RS2 supplement
(PZ0.036) compared with paired t-test. Repeated measures ANOVA
showed a trend for increased glucose uptake with the HAM-RS2 compared
with the placebo (PZ0.077). There was a significantly greater GLP1
response with HAM-RS2 compared with the placebo (PZ0.009) compared
with paired t-test on the iAUC0–120 min.
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46.6 mmol/mol and target UK level for T2DM,
48 mmol/mol), taking oral hypoglycemics, HAM-RS2
intake resulted in a significant improvement in the meal
glucose handling (Fig. 1) without a change in medication,
habitual diet, exercise, or indeed weight loss. There was,
however, no change in the HbA1c following supplemen-
tation, but as the intervention was relatively short
at 12 weeks in patients already at target HbA1c levels, a
longer period may be required for this to become evident.
Although a primary aim of this work was to translate
positive results from individuals at increased risk of
diabetes into those with the condition (3, 7), it is evident
that there are clear differences in the responsiveness
between the patient groups to the dietary change.
Unexpectedly, intravenous insulin sensitivity as assessed
by the hyperinsulinemic clamp technique was not affected
by HAM-RS2 intake, despite a positive improvement in
oral glucose handling. This disparity between i.v. and oral
glucose disposal might imply a gut-mediated factor to be
responsible for the effects, a phenomenon often attributed
to GLP1. Indeed, GLP1, a well-defined incretin, was found
to be elevated postprandially after HAM-RS2 intake, again
a finding which was not found in our previous published
work in those without diabetes (23) but has been reported
in studies of RS in animal models (24). Interestingly, there
was no effect of this elevated GLP1 on postprandial insulin
levels and so any effect on postprandial glucose disposal
may have been through insulin-independent mecha-
nisms. GLP1 has been shown to directly increase muscle
glucose uptake in rodent models (25), with the GLP1
receptor recently localized to human skeletal muscle (26).
GLP1 acutely raises nitric oxide (NO) levels and so acute
changes in both microvascular recruitment (27) and
endothelial function (28) at the level of the muscle are
believed to be involved in this effect. In the current study,
glucose uptake across forearm muscle measured directly
using A-V sampling was increased following HAM-RS2
intake and against a background of elevated GLP1 (Fig. 1)
although failing to reach statistical significance (PZ0.077)
in the 12 patients in whom arterialized blood samples were
obtained. Interestingly, on comparing data obtained from
those with T2DM with results obtained using an identical
technique in metabolic syndrome patients (7), it appeared
that HAM-RS2 intake improved muscle glucose uptake in
T2DM patients to levels found in pre-diabetes/metabolic
syndrome patients. As HAM-RS2 intake in metabolic
syndrome has been shown to normalize glucose uptake
to ‘healthy’ levels, it could be hypothesized that a longer
period of supplementation would have the potential to
improve meal glucose tolerance further in T2DM than
achieved during this initial 12-week investigation.
Other metabolic effects attributed to HAM-RS2 intake,
such as an improved anti-lipolytic activity of insulin in
AT lipolysis, have now also been confirmed in the present
study. Both at fasting and under insulin stimulation during
the clamp, NEFA concentration was significantly decreased,
an effect previously attributed to both stimulation of AT
FFA2/3 receptors directly by products of microbial fermen-
tation (29) and to changes at the transcriptional level (7).
However, it should be noted that HAM-RS2 consumption
did not increase fasting serum SCFA in this study; indeed
butyrate and propionate levels were significantly lowered.
This may be counterintuitive, but earlier work using the
same supplement in healthy individuals also found no
impact on fasting SCFA concentrations (7) and, indeed,
does not discount a change in fecal/luminal concen-
trations, which may be involved in the increased
stimulation ofGLP1 through the FFAR 2/3 receptor. Indeed,
recent work using microbial transfer has demonstrated
that increasing butyrate-producing bacterial species, for
example, does not necessarily result in an increase in
butyrate production, implying that the impact of both
microbes and dietary fibers is more complex than that of
simple SCFA levels (30). An explanation for the lower level
of propionate could be the increased clearance into
peripheral tissue as demonstrated previously (5) although
has yet to be demonstrated in vivo in diabetes. Although
historically the focus of the reduction in NEFA with fiber
feeding has always been in relation to AT content,
paradoxically perhaps, a significant increase in S-IMCL
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Figure 2
Plasma NEFA concentrations during the two-step euglycemic–hyperinsuli-
nemic clamp at the end of 12 weeks supplementation with HAM-RS2
(filled circle) compared with placebo (open circle). MeanCS.E.M.s for 15
patients. Repeated measures ANOVA showed greater differential sup-
pression of NEFA by insulin with the HAM-RS2 compared with the
placebo (PZ0.001).
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was found despite an improvement in glucose tolerance.
We have also previously shown this in people with the
metabolic syndrome in whom there was a substantial
nonsignificant increase (50% increase) in S-IMCL (3).
Ectopic fat storage per se does not cause insulin resistance
(31) and it is hypothesized that the increased partitioning
of FAs toward TG storage in a neutral-lipid droplet may be
beneficial in blunting the lipotoxicity of lipid species such
as ceramides, diacylglycerol (DAG), and fatty acyl coA (32).
Indeed, both a single-exercise session (33) and prolonged
fasting (34) have been shown to partition more FA toward
TG synthesis in skeletal muscle, whereas weight-loss alone
does not (35). In this study, the reduction in fasting plasma
NEFA correlated significantly with the increase in IMCL
in soleus muscle (PZ0.022). Although the peripheral rate
of glucose disposal from the clamp study (Rd) was not
significantly different with HAM-RS2 intake, the change in
Rd correlated significantly with the change in FA flux into
forearm muscle. Combining these lines of evidence
suggests that skeletal muscle is a major metabolic target
for HAM-RS2 in T2DM, as was found previously in
metabolic syndrome. It would be interesting to speculate
whether the molecular changes within muscle tissue
parallel those found with exercise training such as
improved mitochondrial content/function (36).
In accordance with previous data from our group
(5, 7), themetabolic impact of HAM-RS2 intake in diabetes
would appear to be confined to the periphery (AT and
muscle). A new finding in this group of individuals with
diabetes was a reduction in obesity-associated inflam-
mation independent from any changes in body fat volume
per se. Again, as in our previous work in metabolic
syndrome (3, 7), our current study found no evidence for
an effect on hepatic TG storage or the ability of insulin to
inhibit hepatic glucose output (EGP). However, it should
be noted that not all the effects observed on lipids could
be considered beneficial/neutral. A significant increase in
plasma TG was observed in these individuals with T2DM,
nonsignificant increases in TG have been observed by our
group previously, when RS is used in large doses. In the
current study, the increase although statistically signifi-
cant is unlikely to be clinically significant as participants
had TG levels within the reference range. However, the
implication for individuals with baseline hyperlipidemia
is unknown and warrants investigation.
In conclusion, this is the first RS feeding study in
human T2DM where the metabolic effects of RS (rather
than a manipulation of dietary glycemic index/glycemic
load (37)) have been investigated. HAM-RS2 intake
improved meal glucose tolerance in patients with existing
good diabetic-control due to a mechanism which appears
to involve increased muscle uptake of FAs and increased
S-IMCL. However, as a caveat, changes in both ectopic TG
distribution and plasma TG were found, the clinical
significance of which is unknown. Further work is now
warranted to elucidate the molecular mechanisms within
muscle tissue attributable to HAM-RS2, which would
be vital in terms of recommending diet/exercise
interventions to maximize the benefits for muscle glucose
uptake. A larger scale intervention should now be
undertaken in patients using high-fiber foods, with less
well-controlled diabetes and over a longer time frame
before a change to the evidenced-based dietary guidelines
could be proposed.
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